|

CD30.CAR-EBVST cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes

Pipeline

Phase 1: 1

Top Sponsors

  • Baylor College of Medicine1

Indications

  • Classical Hodgkin Lymphoma1
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type1
  • Cancer1

Houston, Texas1 trial

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Houston Methodist Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.